Kamada Ltd
NASDAQ:KMDA
Kamada Ltd
Research & Development
Kamada Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Research & Development
-$12.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Research & Development
-$9.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Research & Development
-$67.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Research & Development
-$5.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Research & Development
-$15.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Research & Development
-₪10.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
Glance View
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
See Also
What is Kamada Ltd's Research & Development?
Research & Development
-12.8m
USD
Based on the financial report for Sep 30, 2025, Kamada Ltd's Research & Development amounts to -12.8m USD.
What is Kamada Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
2%
Over the last year, the Research & Development growth was 19%. The average annual Research & Development growth rates for Kamada Ltd have been 2% over the past three years , 1% over the past five years , and 2% over the past ten years .
